A Phase 2 Randomized Open-Label Controlled Study to Evaluate the Efficacy and Safety of Ampligen in Combination With Standard of Care Versus SOC Alone Following First-Line Therapy in Subjects With Locally Advanced Pancreatic Adenocarcinoma

The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma

开始日期2025-07-01

申办/合作机构

AIM ImmunoTech, Inc.

[+1]

NCT04093323

/ Terminated临床2期IIT

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

开始日期2024-11-13

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT05756166

/ Terminated临床1/2期IIT

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

This phase I/IIa trial tests the safety, side effects, and best dose of chemokine modulation therapy (CKM) (rintatolimod, celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the treatment of patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). CKM drugs such as rintatolimod and interferon alpha 2b work to modify the immune response and tumor-related processes, including tumor cell growth, blood vessel growth, and metastasis. Celecoxib is an anti-inflammatory drug that can cause cell death and may reduce the growth of blood vessels tumors need to grow and spread. Immunotherapy such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CKM therapy prior to pembrolizumab may direct the immune cells to the cancer cells and maximize the effectiveness of pembrolizumab in patients with metastatic or unresectable triple negative breast cancer.

开始日期2024-02-16

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

100 项与安普利近相关的临床结果

登录后查看更多信息

100 项与安普利近相关的转化医学

登录后查看更多信息

100 项与安普利近相关的专利（医药）

登录后查看更多信息

项与安普利近相关的文献（医药）

2024-11-01·Journal for ImmunoTherapy of Cancer

Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer

Article

作者: Attwood, Kristopher ; Wang, Jianming ; Gnjatic, Sacha ; Ioannou, Giorgio ; De Souza, Igor ; Fitzpatrick, Victoria ; Kumar, Prasanna ; Miller, Janine ; Janes, Cayla ; Kalinski, Pawel ; Kokolus, Kathleen M ; Gandhi, Shipra ; Opyrchal, Mateusz ; Young, Jessica ; O’Connor, Tracey ; O'Connor, Tracey ; Roudko, Vladimir ; Levine, Ellis G ; Slomba, Ronald T ; Cortes Gomez, Eduardo ; Kalathil, Suresh ; Cappuccino, Helen ; Ozbey, Sinem ; Takabe, Kazuaki ; Edge, Stephen

Background:

Higher cytotoxic T lymphocyte (CTL) numbers in the tumor microenvironment (TME) predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and positive long-term outcomes in triple-negative breast cancer (TNBC). pCR to NAC is achieved only in 30–40% of patients. The combination of NAC with pembrolizumab increases the pCR rate but at the cost of immune-related adverse events (irAEs). Based on these considerations, we tested if systemic infusion of the chemokine modulatory regimen (CKM; selective toll-like receptor 3 (TLR3) agonist rintatolimod, interferon (IFN)-α2b, and cyclooxygenase-2 (COX-2) inhibitor celecoxib) regimen can be safely combined with NAC to enhance intratumoral CTL numbers and NAC effectiveness.

Methods:

Phase I studyNCT04081389evaluated nine patients with early-stage TNBC who received 3 weeks of paclitaxel with CKM (dose-escalation of IFN-α2b), followed by 9 weeks of paclitaxel alone, dose-dense doxorubicin and cyclophosphamide, and surgery. Primary and secondary endpoints were safety and clinical efficacy, respectively.

Results:

The combination treatment was well-tolerated with no dose-limiting toxicities or irAEs. 5/9 patients achieved pCR and one patient had microinvasive disease (ypTmic). We observed elevated IFN signature and uniform decreases in CTL numbers (average 8.3-fold) in the blood of all treated patients. This was accompanied by reciprocal uniform increases in CD8β (overall 5.9-fold), CD8α/FoxP3 (2.11-fold), and CCL5 (4.73-fold) transcripts in TME, particularly pronounced in patients with pCR. Multiplex immunohistochemistry revealed selectively increased numbers of CTL (but not regulatory T cells) in both the epithelial and stromal tumor compartments and early decreases in the numbers of αSMA+vascular/stromal cells in the tumors of all pCR patients.

Conclusions:

Combined paclitaxel/CKM regimen was safe, with desirable TME changes and preliminary indications of promising pCR+ypTmic of 66%, comparable to the combination of NAC with pembrolizumab.

2024-08-15·Clinical cancer research : an official journal of the American Association for Cancer Research

Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

Article

作者: van Eijck, Casper H.J. ; van Eijck, Casper W.F. ; Mustafa, Dana A.M. ; Aerts, Joachim G.J.V. ; Kucukcelebi, Songul ; Willemsen, Marcella ; Fellah, Amine ; Vadgama, Disha ; Haddaoui, Hassana el

Abstract:

Purpose::

Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC.

Experimental Design::

Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models.

Results::

Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1.

Conclusions::

This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.See related commentary by Martínez-Riaño et al., p. 3355

2023-11-01·Journal for immunotherapy of cancer

Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx

Article

作者: Kokolus, Kathleen M ; Wallace, Paul K ; Attwood, Kristopher ; Grimm, Melissa J ; Slomba, Ronald T ; Witkiewicz, Agnieszka ; O'Connor, Tracey L ; Minderman, Hans ; Williams, Lauren ; Groman, Adrienne ; Levine, Ellis G ; Kalinski, Pawel ; Soh, Kah Teong ; Early, Amy P ; Maguire, Orla ; Opyrchal, Mateusz ; Gandhi, Shipra ; Tarquini, Mary Lynne

Background:

Presence of cytotoxic T lymphocytes (CTL) in the tumor microenvironment (TME) predicts the effectiveness of cancer immunotherapies. The ability of toll-like receptor 3 (TLR3) ligands, interferons (IFNs) and COX2 inhibitors to synergistically induce CTL-attracting chemokines (but not regulatory T cell (Treg)-attractants) in the TME, but not in healthy tissues, observed in our preclinical studies, suggested that their systemic application can reprogram local TMEs.

Methods:

Six evaluable patients (33–69 years) with metastatic triple-negative breast cancer received six doses of systemic chemokine-modulating (CKM) regimen composed of TLR3 ligand (rintatolimod; 200 mg; intravenous), IFN-α2b (20 MU/m2; intravenous) and COX2 inhibitor (celecoxib; 2×200 mg; oral) over 2 weeks. The predetermined primary endpoint was the intratumoral change in the expression of CTL marker, CD8α, in the post-CKM versus pre-CKM tumor biopsies. Patients received follow-up pembrolizumab (200 mg, intravenously, every 3 weeks), starting 3–8 days after completion of CKM.

Results:

Post-CKM biopsies showed selectively increased CTL markers CD8α (average 10.2-fold, median 5.5-fold, p=0.034) and granzyme B (GZMB; 6.1-fold, median 5.8-fold, p=0.02), but not FOXP3 (Treg marker) relative to HPRT1 expression, resulting in the increases in average CD8α/FOXP3 ratio and GZMB/FOXP3 ratio. CKM increased intratumoral CTL-attractants CCL5 and CXCL10, but not Treg-attractants CCL22 or CXCL12. In contrast, CD8+T cells and their CXCR3+subset showed transient decreases in blood. One clinical response (breast tumor autoamputation) and three stable diseases were observed. The patient with clinical response remains disease free, with a follow-up of 46 months as of data cut-off.

Conclusions:

Short-term systemic CKM selectively increases CTL numbers and CTL/Treg ratios in the TME, while transiently decreasing CTL numbers in the blood. Transient effects of CKM suggest that its simultaneous application with checkpoint blockade and other forms of immunotherapy may be needed for optimal outcomes.

150

项与安普利近相关的新闻（医药）

2025-07-02

·GlobeNewswire-Health Care

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

OCALA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a presentation and discussion on immunotherapies involving AIM’s drug Ampligen at the recent U.S.-Poland Science and Technology Symposium 2025, held June 17–20, 2025, across Silicon Valley, San Francisco and Stanford University. Pawel Kalinski, MD, PhD, a world-renowned research oncologist, presented on the drug and participated in a discussion session titled Revolution in Healthcare. Dr. Kalinski has been a senior investigator for multiple oncology clinical studies involving Ampligen, which has been studied for conditions such as solid tumors, viral diseases and disorders of the immune system. In his presentation and panel discussion, Dr. Kalinski presented his work with Ampligen as evidence of the potential successes that private-public partnerships can produce if companies, institutions and governmental agencies work together via joint clinical trials in the development of new treatments and therapies. Specifically, Dr. Kalinski believes that there is great potential to expand within the United States as well as Poland and other Central and Eastern European Countries, through such initiatives as the Translational Research Cancer Centers Consortium, or Marie Sklodowska-Curie Symposia on Cancer Research and Care (5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care). This year’s conference theme was “Opportunities in Singularity.” The conference was organized by the US-Poland Science and Technology Symposium in partnership with Taube philanthropies, the Consulate General of the Republic of Poland in Los Angeles, leading Polish universities, the Council of Polish Engineers in North America and Top 500 Innovators alumni. AIM CEO Thomas K. Equels stated: “We can advance cancer research rapidly if we work together. This combined determination can pair innovative therapies with the critical funding needed to turn promising ideas into successful actions. In fact, putting this concept into practice will be one of my main goals at the upcoming Marie Sklodowska-Curie Symposia on Cancer Research & Care in Warsaw, Poland in September, where I will be working to establish government- and industry-funded clinical partnerships and potential licensing agreements in Europe, with an emphasis on Poland.” About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com

免疫疗法ASCO会议

2025-06-17

·EINPresswire

AIM ImmunoTech Resumes Trading on NYSE American

Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th OCALA, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that its common stock has resumed trading on the NYSE American under the symbol "AIM" and CUSIP 00901B303, effective at the start of trading today, June 17, 2025. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook . Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

免疫疗法

2025-06-12

·GlobeNewswire-Health Care

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMID) (“AIM” or the “Company”) today announced the United States Patent and Trademark Office has granted U.S. patent No. 12312376, titled “Therapeutic Double Stranded RNA and Methods for Producing the Same.” The patent expires January 25, 2041. The new patent covers methods involving the manufacture of a range of therapeutic double-stranded RNA (dsRNA) products, of which Ampligen is included. Combined with AIM’s multiple compositions and methods patents involving Ampligen, this manufacturing patent, along with AIM’s other issued patents, further secures the Company’s control over the synthesis and use of the first-in-class drug, and provides patent protection for manufacturing until 2041. The new patent significantly extends the potential development runway for the drug, securing AIM additional time to safely and confidently develop its drug program as it seeks U.S. Food and Drug Administration (“FDA”) approval for Ampligen in any of a series of indications. Ampligen has demonstrated broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. AIM’s overall intellectual property portfolio covers the manufacture and use of Ampligen. AIM’s patents include Ampligen in the treatment of cancer (U.S. patent 11,813,279, expires August 9, 2039), the Post-COVID condition of fatigue (Netherlands’ patent 2032813, expires August 21, 2042) and endometriosis (U.S. patent 12,102,649, expires October 22, 2040). AIM CEO Thomas K. Equels commented, “This patent is a significant milestone for AIM as it represents the final step in a multi-year project to strengthen and secure our global patent portfolio surrounding Ampligen. AIM now has extended patent protection for the manufacture of Ampligen, the composition of Ampligen and the way in which Ampligen can be utilized as a therapeutic for a diverse collection of unmet medical needs, from deadly cancers to Post-COVID conditions to endometriosis.” Significantly, AIM’s intellectual property protection for Ampligen also includes multiple Orphan Drug Designations (“ODD”) from the FDA and the European Medicines Agency (“EMA”). FDA designation grants seven years of market exclusivity after commercial approval and EMA designation grants 10 years of market exclusivity after such approval. AIM’s orphan drug designations include Metastatic Melanoma (US), Renal Cell Carcinoma (US), Pancreatic Adenocarcinoma (US and EU), Ebola Virus Disease (US and EU), Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (US) and HIV (US). About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a prophylactic or therapy for any indication. The granting of patents and Orphan Medicinal Production Designation, while beneficial, do not assure commercial approval. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com

孤儿药免疫疗法

100 项与安普利近相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09661	安普利近	L03A	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
慢性疲劳综合征	阿根廷	AIM ImmunoTech, Inc.	2017-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期胰腺腺癌	临床2期	美国	AIM ImmunoTech, Inc.	2025-07-01
转移性胰腺癌	临床2期	荷兰	AIM ImmunoTech, Inc.	2024-01-09
转移性胰腺癌	临床2期	荷兰	AstraZeneca PLC	2024-01-09
转移性胰腺导管腺癌	临床2期	荷兰	AstraZeneca PLC	2024-01-09
转移性胰腺导管腺癌	临床2期	荷兰	AIM ImmunoTech, Inc.	2024-01-09
新冠肺炎后遗症	临床2期	美国	AIM ImmunoTech, Inc.	2023-06-30
结直肠癌	临床2期	-	AIM ImmunoTech, Inc.	2022-04-11
急性白血病	临床2期	美国	Roswell Park Comprehensive Cancer Center	2020-11-17
慢性淋巴细胞白血病	临床2期	美国	Roswell Park Comprehensive Cancer Center	2020-11-17
新型冠状病毒感染	临床2期	美国	Roswell Park Comprehensive Cancer Center	2020-11-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05592418 (AMP-518, CTgov)	临床2期	新冠肺炎后遗症	80	Rintatolimod (Ampligen / Rintatolimod)	構積膚顧衊鹹簾衊鑰願(壓築窪廠觸積繭衊餘繭) = 襯窪糧壓壓製築衊鏇範醖夢顧構網廠願齋築齋 (窪繭衊築廠衊選衊構憲, 9.31) 更多	-	2025-01-22
NCT05592418 (AMP-518, CTgov)	临床2期	新冠肺炎后遗症	80	Placebo / Normal Saline (Placebo / Saline)	構積膚顧衊鹹簾衊鑰願(壓築窪廠觸積繭衊餘繭) = 襯鹽壓廠構蓋膚觸鑰鹹醖夢顧構網廠願齋築齋 (窪繭衊築廠衊選衊構憲, 7.51) 更多	-	2025-01-22
NCT05592418 (AMP-518, Corporate Publications) 人工标引	临床2期	新冠肺炎后遗症	66	Ampligen	餘簾鏇網鹽範獵鏇壓範(築遞繭窪夢積積選鏇簾) = between the Ampligen and placebo groups reached or approached statistical significance at several timepoints during the treatment phase. 鑰觸範遞網遞積構廠積 (糧淵壓製鬱製鹽憲鏇蓋 ) 更多	积极	2024-02-08
NCT05592418 (AMP-518, Corporate Publications) 人工标引	临床2期	新冠肺炎后遗症	66	Placebo		积极	2024-02-08
NCT03734692 (GlobeNewswire) 人工标引	临床2期	复发性卵巢癌	-	Ampligen+pembrolizumab	選窪觸憲積顧網醖構製(壓獵糧製衊膚願艱艱蓋) = Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors 顧廠顧艱憲鬱夢網遞餘 (憲獵遞製膚獵願蓋蓋憲 )	积极	2023-11-08
NCT04081389 (Phase I study, CTgov)	临床1期	三阴性乳腺癌 \| 早期乳腺癌	9	Interferon Alpha-2b (Arm 1: Interferon Alpha-2b at DL 1)	遞廠範積醖鑰簾餘繭鬱 = 遞廠獵衊醖遞蓋獵鹹積願壓構衊鑰觸膚鬱襯選 (蓋網製網鏇選夢艱鬱鹽, 積鏇淵襯遞醖憲鑰鬱衊 ~ 構憲選願顧觸蓋願壓衊) 更多	-	2023-09-11
NCT04081389 (Phase I study, CTgov)	临床1期	三阴性乳腺癌 \| 早期乳腺癌	9	Interferon Alpha-2b (Arm 2: Interferon Alpha-2b at DL 2)	遞廠範積醖鑰簾餘繭鬱 = 積壓夢膚壓繭獵膚觸遞願壓構衊鑰觸膚鬱襯選 (蓋網製網鏇選夢艱鬱鹽, 衊糧窪簾壓鏇壓膚鑰鏇 ~ 網衊膚衊夢顧餘窪廠蓋) 更多	-	2023-09-11
Corporate Publications 人工标引	临床1期	-	40	Rintatolimod	壓餘鹹鏇廠鹹觸壓構膚(觸製襯鑰膚艱淵網簾膚) = 蓋積製膚築構廠衊繭夢選糧築簾觸網範淵蓋襯 (構淵鬱繭製衊鏇夢鹽襯 )	积极	2022-12-08
Corporate Publications 人工标引	临床1期	-	40	Placebo	壓餘鹹鏇廠鹹觸壓構膚(觸製襯鑰膚艱淵網簾膚) = 窪遞簾窪鬱淵簾獵鏇鑰選糧築簾觸網範淵蓋襯 (構淵鬱繭製衊鏇夢鹽襯 )	积极	2022-12-08
NCT04081389 (SITC2022) 人工标引	临床1期	三阴性乳腺癌 ER Negative \| HER2 Negative \| PR Negative	9	celecoxib+interferon (IFN)-α2b+rintatolimod	鑰糧憲衊餘醖窪廠鹹鹹(窪窪繭獵鑰顧蓋餘簾網) = 觸膚衊壓壓衊構鑰餘窪壓淵積鹽願憲鑰憲廠遞 (壓鑰鹹築壓選觸積窪顧 ) 更多	积极	2022-11-01
NCT00215813 (AMP-511, Biospace) 人工标引	N/A	新冠肺炎后遗症	4	Rintatolimod	淵網積齋鏇憲艱膚齋觸(醖鹹構觸繭簾觸艱遞窪) = The preliminary data from this uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with Ampligen 鏇餘憲構鹽鏇壓齋製齋 (積餘鏇憲醖醖觸顧衊衊 )	积极	2022-07-28
NCT03403634 (AACR2022) 人工标引	临床2期	结直肠癌肝转移 Microsatellite Stable (MSS)	12	celecoxib+IFNα2b IV+rintatolimod	構獵選齋顧淵窪艱簾鑰(觸壓夢繭觸選築艱網鏇) = increased 醖廠壓鬱簾獵齋衊積襯 (膚餘窪築夢壓積範廠顧 ) 达到更多	积极	2022-06-15
NCT03599453 (AACR2022)	早期临床1期	转移性三阴性乳腺癌	6	Systemic rintatolimod and interferon-α2b	遞鬱艱遞憲選鏇齋願製(膚範淵夢窪鏇網獵選鬱) = 鹽夢夢衊鑰選艱糧膚簾鬱鏇鏇鹹積艱網鬱壓衊 (膚憲獵鑰製餘積醖觸簾 ) 更多	-	2022-06-15
NCT03599453 (GlobeNewswire) 人工标引	临床1期	转移性三阴性乳腺癌 Triple Negative	6	IFN-2+Celecoxib+Ampligen+Pembrolizumab	繭顧簾窪簾襯願艱憲壓(餘窪製積積淵構蓋淵選) = 觸鏇築襯顧艱選艱蓋壓餘醖鏇構願蓋艱蓋蓋夢 (鬱選壓鬱遞製夢襯簾構 ) 更多	积极	2022-04-11